Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
6.28
-0.31 (-4.70%)
May 1, 2025, 4:00 PM EDT - Market closed
Coya Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Coya Therapeutics stock have an average target of 17, with a low estimate of 14 and a high estimate of 18. The average target predicts an increase of 170.70% from the current stock price of 6.28.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Coya Therapeutics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +122.93% | Apr 28, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $18 | Strong Buy | Maintains | $18 | +186.62% | Apr 24, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $18 | Strong Buy | Maintains | $18 | +186.62% | Apr 22, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $18 | Strong Buy | Maintains | $18 | +186.62% | Mar 27, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +122.93% | Mar 20, 2025 |
Financial Forecast
Revenue This Year
6.91M
from 3.55M
Increased by 94.45%
Revenue Next Year
n/a
from 6.91M
EPS This Year
-1.03
from -0.98
EPS Next Year
-1.55
from -1.03
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 9.6M | n/a | 15.8M | ||
| Avg | 6.9M | n/a | 12.8M | ||
| Low | 2.1M | n/a | 9.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 168.8% | - | - | ||
| Avg | 94.5% | - | - | ||
| Low | -42.1% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.78 | -1.51 | -0.69 | ||
| Avg | -1.03 | -1.55 | -0.86 | ||
| Low | -1.31 | -1.56 | -1.00 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.